WIXOM, Mich., Oct. 29, 2008 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a specialty pharma company focused on drug and device development in the renal market, reported today that the independent Data Safety Monitoring Board (DSMB) providing oversight for the SFP Phase II-b iron maintenance therapy dose-range study reviewed the cumulative safety data from the ongoing clinical study and informed the Company that it has identified no safety concerns. The DSMB also recommended the continuation of the study with no modifications.
